Table 4.
Age, PSA, prostate volume and biopsy outcomes of all 19 men.
| Patient code | Age (year) | PSA at biopsy (ng/mL) | Prostate volume (mL) | MRI highest PIRADS | rTPB |
MRTB |
||
|---|---|---|---|---|---|---|---|---|
| No. positive cores/total cores taken | Gleason score | No. positive cores/total cores taken | Gleason score | |||||
| 1 | 75 | 6.2 | 33.3 | 4 | 0/22 | NA | 0/8 | NA |
| 2 | 65 | 8.3 | 40.0 | 4 | 1/28 | 6 | 0/10 | NA |
| 3a | 61 | 5.6 | 31.0 | 5 | 10/26 | 7 | 2/18 | 7 |
| 4 | 71 | 7.0 | 37.0 | 4 | 1/26 | 6 | 0/23 | NA |
| 5 | 59 | 9.7 | 17.5 | 5 | 1/18 | 6 | 2/18 | 6 |
| 6 | 63 | 7.1 | 22.0 | NA | 0/20 | NA | NA | NA |
| 7 | 66 | 8.2 | 37.0 | 4 | 1/27 | 6 | 0/18 | NA |
| 8b | 58 | 5.8 | 21.0 | 4 | 2/24 | 7 | 1/12 | 6 |
| 9 | 68 | 7.6 | 36.6 | 4 | 2/28 | 6 | 0/8 | NA |
| 10c | 68 | 9.9 | 14.0 | 5 | 3/17 | 6 | 12/12 | 7 |
| 11c | 68 | 5.8 | 20.0 | 5 | 2/20 | 6 | 3/6 | 7 |
| 12 | 69 | 10.0 | 49.0 | 3 | 0/32 | NA | 0/6 | NA |
| 13 | 72 | 6.1 | 60.0 | 4 | 3/52 | 6 | 1/19 | 6 |
| 14 | 58 | 4.7 | 58.0 | 3 | 0/38 | NA | 0/24 | NA |
| 15 | 71 | 7.8 | 28.7 | 5 | 2/23 | 6 | 2/17 | 6 |
| 16 | 64 | 4.0 | 32.0 | 3 | 1/25 | 6 | 2/12 | 6 |
| 17a | 61 | 7.0 | 26.0 | 5 | 2/22 | 7 | 2/6 | 7 |
| 18 | 63 | 8.2 | 31.0 | 3 | 0/28 | NA | 0/10 | NA |
| 19 | 63 | 4.7 | 39.0 | 3 | 2/35 | 6 | 1/12 | 6 |
MRTB, magnetic resonance imaging-targeted prostate biopsy; NA, not applicable; PIRADS, Prostate Imaging Reporting and Data System; PSA, prostate specific antigen; rTPB, robotic transperineal template prostate biopsy.
a
Patients upclassified by both MRTB and rTPB.
b
Patients upclassified by rTPB alone.
c
Patients upclassified by MRTB alone.